Systems-Based Discovery Advances Drug Development

Terzic, André

doi:10.1038/clpt.2013.21

Cited by 10 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed a recent analysis revealed that phenotypic screening has been more successful than target-driven screening in delivering first-in-class medicines [18], although also this approach has several pitfalls. Ideally, an appropriate combination of both approaches should be found, to enable researchers to move forward with the best possible candidates [18, 19], and create an effective R&D productivity strategy delivering innovative products with high-quality information [5]. …”

Section: Imi Contribution To Ease the Bottlenecks Of Drug Discoverymentioning

confidence: 99%

The Innovative Medicines Initiative: A Public Private Partnership Model to Foster Drug Discovery

Vaudano

2013

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

The Innovative Medicines Initiative (IMI) is a large-scale public–private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI aims to boost the development of new medicines across Europe by implementing new collaborative endeavours between large pharmaceutical companies and other key actors in the health-care ecosystem, i.e., academic institutions, small and medium enterprises, patients, and regulatory authorities. Currently there are more than 40 IMI projects covering the whole value chain of pharmaceutical R&D, but with a strong focus on drug discovery, as an ideal arena where the PPP concept of pre-competitive collaboration can rapidly deliver results. This article review recent achievements of the IMI consortia of relevance to drug discovery, providing proof-of-concept evidence for the efficiency of this new model of collaboration.

show abstract

Section: Imi Contribution To Ease the Bottlenecks Of Drug Discoverymentioning

confidence: 99%

The Innovative Medicines Initiative: A Public Private Partnership Model to Foster Drug Discovery

Vaudano

2013

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…Indeed, this has led some to differentiate modern phenotypic drug discovery as different due to the inclusion of information regarding potential targets and known pathobiology 111 and systems biology and pharmacology, 112 while others term this emerging blend of methods an integrated systems-level approach to drug discovery. 113…”

Section: Application Of Personalized Medicine Does Not Require Knowledge Of Drug Target Identity or Mechanism Of Actionmentioning

confidence: 99%

Clinical Relevance of Target Identity and Biology: Implications for Drug Discovery and Development

Patel

2013

SLAS Discovery

View full text Add to dashboard Cite

Many of the most commonly used drugs precede techniques for target identification and drug specificity and were developed on the basis of efficacy and safety, an approach referred to as classical pharmacology and, more recently, phenotypic drug discovery. Although substantial gains have been made during the period of focus on target-based approaches, particularly in oncology, these approaches have suffered a high overall failure rate and lower productivity in terms of new drugs when compared with phenotypic approaches. This review considers the importance of target identity and biology in clinical practice from the prescriber's viewpoint. In evaluating influences on prescribing behavior, studies suggest that target identity and mechanism of action are not significant factors in drug choice. Rather, patients and providers consistently value efficacy, safety, and tolerability. Similarly, the Food and Drug Administration requires evidence of safety and efficacy for new drugs but does not require knowledge of drug target identity or target biology. Prescribers do favor drugs with novel mechanisms, but this preference is limited to diseases for which treatments are either not available or suboptimal. Thus, while understanding of drug target and target biology is important from a scientific perspective, it is not particularly important to prescribers, who prioritize efficacy and safety.

show abstract

“…This revolution in clinical care is dependent on molecular diagnostics that predict and prevent disease, enabling the diagnosis and treatment of individual patients and populations [2]. Diagnostic biomarkers are quantifiable disease characteristics that provide information about underlying molecular processes to define disease progression or predict treatment response.…”

mentioning

confidence: 99%

Companion Diagnostics at the Intersection of Personalized Medicine and Healthcare Delivery

Terzic

2015

Biomark. Med.

View full text Add to dashboard Cite

Systems-Based Discovery Advances Drug Development

Cited by 10 publications

References 11 publications

The Innovative Medicines Initiative: A Public Private Partnership Model to Foster Drug Discovery

The Innovative Medicines Initiative: A Public Private Partnership Model to Foster Drug Discovery

Clinical Relevance of Target Identity and Biology: Implications for Drug Discovery and Development

Companion Diagnostics at the Intersection of Personalized Medicine and Healthcare Delivery

Contact Info

Product

Resources

About